Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
周三生物技术催化剂综述-当天结束摘要
- Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume of 8.06 million shares, closed regular trading session at $74.86.
- 百时美施贵宝(纽约证券交易所代码：BMY)和270人传记纳斯达克公司(TSVT)宣布了KarMma-3的TOPLINE阳性结果，该研究是一项3期研究，评估ABECMA(依达卡他汀)与标准联合方案治疗复发和难治的成人多发性骨髓瘤的比较。百时美施贵宝股价在73.95美元至75.32美元的区间内交易，当日成交量为806万股，常规交易时段收于74.86美元。
- Rani Therapeutics (NASDAQ:RANI) announced positive topline results from the single-ascending dose (SAD) portion of its Phase 1 clinical study of its lead asset RT-102 for the potential treatment of osteoporosis. Rani Therapeutics shares traded in a range of $11.03 to $11.51 on a day volume of 13.93 thousand shares, closed regular trading session at $11.10. The company shares are currently trading at $10.75, down 3.2 percent in the after-hours trading session.
- 拉尼治疗公司纳斯达克(Sequoia Capital：RANI)宣布，其铅资产RT-102用于潜在治疗骨质疏松症的第一阶段临床研究的单次递增剂量(SAD)部分获得阳性背线结果。Rani Treateutics的股票交易价格在11.03美元至11.51美元之间，当日成交量为13.93万股，常规交易时段收于11.10美元。该公司股票目前的交易价格为10.75美元，在盘后交易中下跌3.2%。
- The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences' (NASDAQ:RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures. ReShape shares traded in a range of $0.44 to $0.8 on a day volume of 11.26 million shares, closed regular trading session at $0.45.
- 美国食品和药物管理局(FDA)宣布510(K)计划获得批准重塑生命科学纳斯达克：RSLS)胃肠道气囊指示器(GIBI HD)校准管，用于胃和减肥外科手术。重塑股票的交易价格在0.44美元至0.8美元之间，当日成交量为1126万股，常规交易时段收盘时为0.45美元。
- BridgeBio Pharma (NASDAQ:BBIO) and Sentynl Therapeutics announced that the State of Israel Ministry of Health has approved NULIBRY (fosdenopterin) for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency (MoCD) Type A. BridgeBio shares traded in a range of $11.1 to $12.21 on a day volume of 2.04 million shares, closed regular trading session at $11.99.
- 布里奇比奥制药纳斯达克(Sequoia Capital：BBIO)和森特尼治疗公司宣布，以色列卫生部已批准NULIBRY(福登蝶呤)注射，作为以色列第一种治疗A型钼缺乏症的药物，适应症是降低A型钼辅因子缺乏症患者的死亡风险。BridgeBio的股票交易量为204万股，日成交量在11.1美元至12.21美元之间，收盘常规交易时段为11.99美元。
- Lexaria Bioscience (NASDAQ:LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting regarding DehydraTECH-CBD for the treatment of hypertension. Lexaria shares traded in a range of $2.72 to $2.96 on a day volume of 89.16 thousand shares, closed regular trading session at $2.87.
- Lexaria生物科学纳斯达克(Didi Chuxing：Lexx)宣布在新药预研会议上收到了美国食品药品监督管理局(FDA)关于脱氢TECH-CBD治疗高血压的全面积极书面回应。Lexaria的股价在2.72美元至2.96美元的范围内交易，日成交量为89.16万股，常规交易时段收于2.87美元。
- VYNE Therapeutics (NASDAQ:VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). VYNE shares traded in a range of $0.26 to $0.34 on a day volume of 4.75 million shares, closed regular trading session at $0.31.
- Vyne治疗公司纳斯达克公司(Temasek Holdings：Vyne)宣布了评估FMX114治疗轻中度特应性皮炎(AD)的1b/2a阶段临床试验的2a阶段结果。Vyne的股价在0.26美元至0.34美元的范围内交易，当日成交量为475万股，常规交易时段收于0.31美元。
- LianBio (NASDAQ:LIAN) announced the completion of enrollment in the Phase 3 EXPLORER-CN clinical study of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), expect to report topline results in mid-2023. LianBio shares traded in a range of $2.41 to $2.86 on a day volume of 572.39 thousand shares, closed regular trading session at $2.7.
- 联众生物纳斯达克(Sequoia Capital：LIAN)宣布，马伐他汀在中国症状性梗阻性肥厚型心肌病(OHCM)患者中的3期EXPLOR-CN临床研究已经完成，预计将于2023年年中报告TOPLINE结果。LianBio的股价在2.41美元至2.86美元的范围内交易，当日成交量为572.39万股，常规交易时段收于2.7美元。
- TRACON Pharmaceuticals (NASDAQ:TCON) announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of three week safety data from more than 20 patients enrolled into the trial. TRACON shares traded in a range of $1.83 to $2.15 on a day volume of 167.43 thousand shares, closed regular trading session at $2.07. The company shares are currently trading at $2.15, up 3.86 percent in the after-hours trading session.
- TRACON制药公司纳斯达克公司(Temasek Holdings：TCON)宣布，ENVASARC关键试验的独立数据监测委员会在审查了20多名登记参加试验的患者的三周安全数据后，建议试验按计划进行。TRACON股价在1.83美元至2.15美元的区间内交易，当日成交量为167.43万股，常规交易时段收盘报2.07美元。该公司股票目前的交易价格为2.15美元，在盘后交易中上涨了3.86%。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。